Table 4.
Unadjusted and adjusted hazard ratios related to hospitalizations according to IgG subclass levels in the MACRO and STATCOPE cohorts
| MACRO – Time to first Hospitalization | ||||
| IgGa | Univariate analysis | Multivariate analysisb | ||
| Hazard Ratio (95% CI) | P | Hazard Ratio (95% CI) | P | |
| IgG1 | 1.51 (1.16–1.99) | 0.003 | 1.52 (1.15–2.02) | 0.004 |
| IgG2 | 1.37 (1.12–1.67) | 0.002 | 1.33 (1.08–1.64) | 0.007 |
| IgG3 | 1.03 (0.85–1.24) | 0.79 | 1.01 (0.84–1.44) | 0.90 |
| IgG4 | 1.01 (0.89–1.12) | 0.99 | 1.00 (0.88–1.12) | 0.94 |
| STATCOPE – Time to first Hospitalization | ||||
| IgGa | Univariate analysis | Multivariate analysisb | ||
| Hazard Ratio (95% CI) | P | Hazard Ratio (95% CI) | P | |
| IgG1 | 1.33 (0.98–1.80) | 0.07 | 1.27 (0.91–1.76) | 0.16 |
| IgG2 | 1.39 (1.11–1.74) | 0.004 | 1.43 (1.12–1.83) | 0.004 |
| IgG3 | 0.97 (0.79–1.19) | 0.75 | 0.90 (0.73–1.12) | 0.36 |
| IgG4 | 1.08 (0.95–1.22) | 0.22 | 1.06 (0.93–1.20) | 0.39 |
aIgG subclass levels expressed using a negative-log transformation (base 2), with one-unit increase on this log scale being equivalent to a 50% decrease of IgG subclass levels. bAdjusted hazard ratios for IgG levels were calculated using a Cox Proportional Hazards model with adjustments for the following covariates: study drug (azithromycin vs. placebo in MACRO - First cohort; simvastatin vs. placebo in STATCOPE - Replication cohort), age, gender, ethnicity (Caucasian vs. Non-Caucasian), FEV1 (% of predicted values), smoking status (current vs. former smokers), oxygen dependence, inhaled corticosteroid use, and treatment with systemic steroids in previous year. Legend: 95% CI = 95% Confidence Interval